Compare BGI & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGI | SER |
|---|---|---|
| Founded | 1879 | 2017 |
| Country | Canada | United States |
| Employees | N/A | 13 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6M | 19.4M |
| IPO Year | 2002 | N/A |
| Metric | BGI | SER |
|---|---|---|
| Price | $0.77 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 20.9K | ★ 196.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.53 |
| 52 Week High | $1.57 | $7.92 |
| Indicator | BGI | SER |
|---|---|---|
| Relative Strength Index (RSI) | 37.48 | 39.48 |
| Support Level | $0.64 | $1.71 |
| Resistance Level | $0.76 | $4.17 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 25.06 | 32.06 |
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.